Radical Hysterectomy for FIGO Stage I-IIB Adenocarcinoma of the Uterine Cervix

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Apr 30

PMID 19401699

Citations 33

Authors

T Kasamatsu

T Onda

M Sawada

T Kato

S Ikeda

Y Sasajima

H Tsuda

Affiliations

Soon will be listed here.

Abstract

A retrospective analysis was carried out to identify risk factors for survival and relapse in patients with FIGO stage I-IIB cervical adenocarcinoma (AC), who underwent radical hysterectomy, and to compare outcome and spread pattern with those of squamous cell carcinoma (SCC). One hundred and twenty-three FIGO stage I-IIB patients with AC and 455 patients with SCC, who all underwent primary radical hysterectomy, were reviewed. Among the patients with AC, Cox model identified tumour size (95% CI: 1.35-30.71) and node metastasis (95% CI: 5.09-53.44) as independent prognostic factors for survival, and infiltration to vagina (95% CI: 1.15-5.76) and node metastasis (95% CI: 6.39-58.87) as independent prognostic factors for relapse. No significant difference was found in survival or relapse between the AC and SCC groups, after adjusting for other clinicopathological characteristics using Cox model. No significant difference was found in the positive rates of lymph nodes or location of initial failure sites between the two groups, but ovarian metastatic rate was significantly higher in patients with pathologic stage IIB AC (P=0.02). Positive node is a common independent prognostic factor for survival and relapse of patients with AC. FIGO stage I-IIB patients with AC or SCC, who underwent radical hysterectomy, have similar prognosis and spread pattern, but different ovarian metastasis rates.

Citing Articles

Predictive Role of Preoperative Whole-Body 18F-FDG PET/CT for Risk Stratification of Early-Stage (FIGO I-IIA) Cervical Cancer Patients Treated by Surgery.

Singaram N, Hulikal N, Manthri R, Chowhan A Cureus. 2024; 16(1):e53107.

PMID: 38283777 PMC: 10822672. DOI: 10.7759/cureus.53107.

Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14-year multicenter study.

Ye Y, Zhang G, Li Z, Chen B, Zhao H, Yang Y Cancer Med. 2023; 12(19):19617-19632.

PMID: 37768092 PMC: 10587947. DOI: 10.1002/cam4.6586.

Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.

Bulutay P, Eren O, Ozen O, Haberal A, Kapucuoglu N Turk J Obstet Gynecol. 2023; 20(3):164-173.

PMID: 37667475 PMC: 10478723. DOI: 10.4274/tjod.galenos.2023.62819.

Impact of different post-operative treatment modalities on long-term outcomes in International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIICp cervical cancer.

Soochit A, Zhang C, Feng Y, Luo X, Huang H, Liu J Int J Gynecol Cancer. 2023; 33(6):882-889.

PMID: 37001894 PMC: 10314006. DOI: 10.1136/ijgc-2022-004234.

Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy.

Cho W, Kim H, Park W, Chang C, Lee Y, Choi C J Gynecol Oncol. 2022; 33(6):e71.

PMID: 36047374 PMC: 9634092. DOI: 10.3802/jgo.2022.33.e71.

References

Berek J . Radiation therapy for adenocarcinoma of the uterine cervix: does the histology matter?. Int J Radiat Oncol Biol Phys. 1995; 32(5):1543-4. DOI: 10.1016/0360-3016(95)00260-6. View

Suprasert P, Srisomboon J, Kasamatsu T . Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer. 2005; 15(6):995-1001. DOI: 10.1111/j.1525-1438.2005.00259.x. View

Drescher C, Hopkins M, Roberts J . Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcinoma of the uterine cervix. Gynecol Oncol. 1989; 33(3):340-3. DOI: 10.1016/0090-8258(89)90524-6. View

Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R . Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol. 2000; 26(5):464-7. DOI: 10.1053/ejso.1999.0923. View

Eifel P, Burke T, Morris M, Smith T . Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995; 59(1):38-44. DOI: 10.1006/gyno.1995.1265. View

Eifel P, Morris M, Oswald M, Wharton J, DELCLOS L . Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer. 1990; 65(11):2507-14. DOI: 10.1002/1097-0142(19900601)65:11<2507::aid-cncr2820651120>3.0.co;2-9. View

Ishikawa H, Nakanishi T, Inoue T, Kuzuya K . Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol. 1999; 73(1):42-6. DOI: 10.1006/gyno.1998.5291. View

Look K, Brunetto V, Clarke-Pearson D, AVERETTE H, Major F, Alvarez R . An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 63(3):304-11. DOI: 10.1006/gyno.1996.0327. View

Alfsen G, Kristensen G, Skovlund E, Pettersen E, Abeler V . Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer. 2001; 92(9):2471-83. DOI: 10.1002/1097-0142(20011101)92:9<2471::aid-cncr1597>3.0.co;2-k. View

10.

Lea J, Coleman R, Garner E, Duska L, Miller D, Schorge J . Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003; 91(3):558-62. DOI: 10.1016/j.ygyno.2003.08.020. View

11.

Korhonen M . Adenocarcinoma of the uterine cervix. Prognosis and prognostic significance of histology. Cancer. 1984; 53(8):1760-3. DOI: 10.1002/1097-0142(19840415)53:8<1760::aid-cncr2820530824>3.0.co;2-4. View

12.

Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, Heintz A . Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2004; 83 Suppl 1:41-78. DOI: 10.1016/s0020-7292(03)90115-9. View

13.

Smith H, Tiffany M, Qualls C, Key C . The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol. 2000; 78(2):97-105. DOI: 10.1006/gyno.2000.5826. View

14.

Piver M, Rutledge F, Smith J . Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974; 44(2):265-72. View

15.

Matthews C, Burke T, Tornos C, Eifel P, Atkinson E, Stringer C . Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. Gynecol Oncol. 1993; 49(1):19-23. DOI: 10.1006/gyno.1993.1079. View

16.

Fregnani J, Soares F, Novik P, Lopes A, Latorre M . Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. Eur J Obstet Gynecol Reprod Biol. 2006; 136(2):215-23. DOI: 10.1016/j.ejogrb.2006.10.021. View

17.

Nakanishi T, Wakai K, Ishikawa H, Nawa A, Suzuki Y, Nakamura S . A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol. 2001; 82(3):504-9. DOI: 10.1006/gyno.2001.6316. View

18.

Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J . Does histology influence prognosis in patients with early-stage cervical carcinoma?. Cancer. 2001; 92(12):2999-3004. DOI: 10.1002/1097-0142(20011215)92:12<2999::aid-cncr10145>3.0.co;2-1. View

19.

Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K . A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000; 79(2):289-93. DOI: 10.1006/gyno.2000.5935. View

20.

Lee K, Lee J, Park C, Lee K, Cho H, Ha S . What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer. 2006; 16(4):1569-73. DOI: 10.1111/j.1525-1438.2006.00628.x. View